251 related articles for article (PubMed ID: 35641994)
1. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
Kwong A; Ho CYS; Shin VY; Au CH; Chan TL; Ma ESK
BMC Med Genomics; 2022 May; 15(1):122. PubMed ID: 35641994
[TBL] [Abstract][Full Text] [Related]
2. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
3. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract][Full Text] [Related]
4. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH
Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706
[TBL] [Abstract][Full Text] [Related]
5. Challenges in periodic revision of genetic testing results: Comparison of the main classification guidelines and report of a retrospective analysis involving BRCA1/BRCA2 variants of uncertain significance.
Andreis TF; de Souza KIW; Vieira IA; Alemar B; Sinigaglia M; de Araújo Rocha YM; Artigalás O; Bittar C; Oliveira Netto CB; Ashton-Prolla P; Rosset C
Gene; 2023 Apr; 862():147281. PubMed ID: 36775216
[TBL] [Abstract][Full Text] [Related]
6. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
7. Reclassification of
Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
[TBL] [Abstract][Full Text] [Related]
8. Reclassification of
Ha HI; Ryu JS; Shim H; Kong SY; Lim MC
J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592
[TBL] [Abstract][Full Text] [Related]
9. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
[TBL] [Abstract][Full Text] [Related]
10. Changes in classification of genetic variants in BRCA1 and BRCA2.
Kast K; Wimberger P; Arnold N
Arch Gynecol Obstet; 2018 Feb; 297(2):279-280. PubMed ID: 29302806
[TBL] [Abstract][Full Text] [Related]
11. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
12. Functional Categorization of
Bouwman P; van der Heijden I; van der Gulden H; de Bruijn R; Braspenning ME; Moghadasi S; Wessels LFA; ; Vreeswijk MPG; Jonkers J
Clin Cancer Res; 2020 Sep; 26(17):4559-4568. PubMed ID: 32546644
[TBL] [Abstract][Full Text] [Related]
13. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
Park KS; Cho EY; Nam SJ; Ki CS; Kim JW
Genet Med; 2016 Dec; 18(12):1250-1257. PubMed ID: 27124784
[TBL] [Abstract][Full Text] [Related]
16.
Lourenço RA; Lança M; Monteiro Gil O; Cardoso J; Lourenço T; Pereira-Leal JB; Rodrigues AS; Rueff J; Nunes Silva S
Mol Med Rep; 2023 Jul; 28(1):. PubMed ID: 37232349
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.
Lindor NM; Goldgar DE; Tavtigian SV; Plon SE; Couch FJ
Oncologist; 2013; 18(5):518-24. PubMed ID: 23615697
[TBL] [Abstract][Full Text] [Related]
18. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
19. Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Kim HK; Lee EJ; Lee YJ; Kim J; Kim Y; Kim K; Lee SW; Chang S; Lee YJ; Lee JW; Lee W; Chun S; Son BH; Jung KH; Kim YM; Min WK; Ahn SH
J Hum Genet; 2020 Mar; 65(3):209-220. PubMed ID: 31907386
[TBL] [Abstract][Full Text] [Related]
20. Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
Li H; LaDuca H; Pesaran T; Chao EC; Dolinsky JS; Parsons M; Spurdle AB; Polley EC; Shimelis H; Hart SN; Hu C; Couch FJ; Goldgar DE
Genet Med; 2020 Apr; 22(4):701-708. PubMed ID: 31853058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]